Has Christopher Mancuso, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,049 in general payments to Christopher Mancuso, MD across 30 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Mancuso, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Mancuso, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Mancuso, MD

Sports Medicine · West Reading, PANPI 1568464378

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (39.9%), education and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Arthrex at 47.3% of the total. 2024 is the largest year on record at $1,358, more than ten times the $37 reported in 2019.

$3,049in general payments, 2019–2025

Across 30 payments — averaging $101.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Arthrex$1K
Novus Surgical Solutions LLC$1K
Novus Surgical Consultants$284
Johnson & Johnson$49
Baxter Healthcare$39
Mayne Pharma Commercial LLC$28
plus $9 from 1 others

$33,073in research payments, 2019–2025

Across 12 payments — averaging $2756.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$33K

What the payments were for

Travel & lodging$1,21840%
Food & beverage$59319%
Education$1,20039%
Other$391%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Arthrex	18	$1,441
Novus Surgical Solutions LLC	1	$1,200
Novus Surgical Consultants	7	$284
Johnson & Johnson	1	$49
Baxter Healthcare	1	$39
Mayne Pharma Commercial LLC	1	$28
Heraeus Medical, LLC.	1	$9

How this compares

$3,049 in reported general payments places this provider in the 70th percentile of 311 sports medicine providers in Pennsylvania.

See all sports medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$256,409

Medicare patients

820

Services billed

5,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Meloxicam	219	$821
Celecoxib	13	$300

Paid to pharmacies, not to this prescriber.